Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

Irbaz Bin Riaz; Qurat Ul Ain Riaz Sipra; Syed Arsalan Ahmed Naqvi; Huan He; Rabbia Siddiqi; Mahnoor Islam; Noureen Asghar; Waleed Ikram; Wenxin Xu; Hongfong Liu; Parminder Singh; Thai Huu Ho; Mehmet Asim Bilen; Yousef Zakharia; Alan Haruo Bryce; Mohammad Hassan Murad

doi:10.1016/j.critrevonc.2022.103706

Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

Irbaz Bin Riaz, Qurat Ul Ain Riaz Sipra, Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Waleed Ikram, Wenxin Xu, Hongfong Liu, Parminder Singh, Thai Huu Ho, Mehmet Asim Bilen, Yousef Zakharia, Alan Haruo Bryce, Mohammad Hassan Murad

Research output: Contribution to journal › Review article › peer-review

Abstract

Objective: To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups. Methods: This ‘living’ review was conducted using Living Interactive Evidence (LIvE) synthesis framework. Results: The ‘living’ results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores. Conclusion: Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.

Original language	English (US)
Article number	103706
Journal	Critical Reviews in Oncology/Hematology
Volume	175
DOIs	https://doi.org/10.1016/j.critrevonc.2022.103706
State	Published - Jul 2022

Keywords

Baseline risk
Immunotherapy
Living evidence
Pembrolizumab
Renal cell carcinoma

ASJC Scopus subject areas

Geriatrics and Gerontology
Hematology
Oncology

Access to Document

10.1016/j.critrevonc.2022.103706

Cite this

Riaz, I. B., Sipra, Q. U. A. R., Naqvi, S. A. A., He, H., Siddiqi, R., Islam, M., Asghar, N., Ikram, W., Xu, W., Liu, H., Singh, P., Ho, T. H., Bilen, M. A., Zakharia, Y., Bryce, A. H., & Murad, M. H. (2022). Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 175, Article 103706. https://doi.org/10.1016/j.critrevonc.2022.103706

Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. / Riaz, Irbaz Bin; Sipra, Qurat Ul Ain Riaz; Naqvi, Syed Arsalan Ahmed et al.
In: Critical Reviews in Oncology/Hematology, Vol. 175, 103706, 07.2022.

Research output: Contribution to journal › Review article › peer-review

Riaz, IB, Sipra, QUAR, Naqvi, SAA, He, H, Siddiqi, R, Islam, M, Asghar, N, Ikram, W, Xu, W, Liu, H, Singh, P , Ho, TH, Bilen, MA, Zakharia, Y, Bryce, AH & Murad, MH 2022, 'Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis', Critical Reviews in Oncology/Hematology, vol. 175, 103706. https://doi.org/10.1016/j.critrevonc.2022.103706

@article{34077a944f0648b690631d4deb3c0f35,

title = "Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis",

abstract = "Objective: To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups. Methods: This {\textquoteleft}living{\textquoteright} review was conducted using Living Interactive Evidence (LIvE) synthesis framework. Results: The {\textquoteleft}living{\textquoteright} results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores. Conclusion: Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.",

keywords = "Baseline risk, Immunotherapy, Living evidence, Pembrolizumab, Renal cell carcinoma",

author = "Riaz, {Irbaz Bin} and Sipra, {Qurat Ul Ain Riaz} and Naqvi, {Syed Arsalan Ahmed} and Huan He and Rabbia Siddiqi and Mahnoor Islam and Noureen Asghar and Waleed Ikram and Wenxin Xu and Hongfong Liu and Parminder Singh and Ho, {Thai Huu} and Bilen, {Mehmet Asim} and Yousef Zakharia and Bryce, {Alan Haruo} and Murad, {Mohammad Hassan}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = jul,

doi = "10.1016/j.critrevonc.2022.103706",

language = "English (US)",

volume = "175",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma

T2 - A living interactive systematic review and network meta-analysis

AU - Riaz, Irbaz Bin

AU - Sipra, Qurat Ul Ain Riaz

AU - Naqvi, Syed Arsalan Ahmed

AU - He, Huan

AU - Siddiqi, Rabbia

AU - Islam, Mahnoor

AU - Asghar, Noureen

AU - Ikram, Waleed

AU - Xu, Wenxin

AU - Liu, Hongfong

AU - Singh, Parminder

AU - Ho, Thai Huu

AU - Bilen, Mehmet Asim

AU - Zakharia, Yousef

AU - Bryce, Alan Haruo

AU - Murad, Mohammad Hassan

PY - 2022/7

Y1 - 2022/7

N2 - Objective: To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups. Methods: This ‘living’ review was conducted using Living Interactive Evidence (LIvE) synthesis framework. Results: The ‘living’ results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores. Conclusion: Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.

AB - Objective: To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups. Methods: This ‘living’ review was conducted using Living Interactive Evidence (LIvE) synthesis framework. Results: The ‘living’ results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores. Conclusion: Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.

KW - Baseline risk

KW - Immunotherapy

KW - Living evidence

KW - Pembrolizumab

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85130952366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130952366&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2022.103706

DO - 10.1016/j.critrevonc.2022.103706

M3 - Review article

C2 - 35537621

AN - SCOPUS:85130952366

SN - 1040-8428

VL - 175

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103706

ER -

Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this